Dose response to inhaled corticosteroids: Benefits and risks

Seminars in Respiratory and Critical Care Medicine

Volumn 19, Issue 6, 1998, Pages 625-646

  Lipworth, Brian J ^a   Wilson, Andrew M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adrenal; Asthma; Bone; Bruising; Budesonide; Cataract; Corticosteroid; Dose response; Fluticasone; Growth; Meta analysis; Pharmacokinetics; Prednisone; Triamcinolone

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETAMETHASONE VALERATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE ACETONIDE;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ARTICLE; ASTHMA; CHILD GROWTH; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; GROWTH RETARDATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; OSTEOPOROSIS; POWDER INHALER; PRIORITY JOURNAL;

EID: 0032419991     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1009437     Document Type: Article

References (158)

1. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52(suppl 1):S1-S21
2. National Asthma Education and Prevention Programme. Expert panel report II. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997. Publication 97-4051
3. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-224
4. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-1488
5. Pauwels R, Lofdahl CG, Postma D, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-1411
6. Reiss TF, Chervinsky P, Dockhurn KJ, Shingo S, et al. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicenter, randomized double-blind trial. Arch Int Med 1998;158:1213-1220
7. Knorr B, Matz J, Burnstein JA, et al. Montelukast for chronic asthma in 6-14 year old children. JAMA 1998; 279:1181-1186
8. Johansson SA, Anderson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dopropionate in man. Eur J Clin Pharmcol 1982;22:523-529
9. Phillips GH. Structure-activity relationships of topically active steroids: The selection of fluticasone propionate. Respir Med 1990;84(suppl A):19-23
10. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149(suppl):A212
11. Anderson N, Klint S, Randwall G, et al. Equipotency of budesonide and fluticasone propionate in the vasoconstrictor assay. Thorax 1994;49:422P
12. Barnes NC, Marone G, Di Maria GV, Visser S, Utama I, Payne SI. A comparison of fluticasone propionate 1 mg daily, with beclomethasone dipropionate 2 mg daily, in the treatment of severe asthma. Eur Respir J 1993;6: 877-884
13. Lundback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500 mg/day) administered either as dry powder via a diskhaler inhaler or pressurized inhaler and compared with beclomethasone type propionate (1000 μg/day) administered by pressurized inhaler. Respir Med 1993;87:609-620
14. Lorentzen KA, Van Helmon JLM, Bauer K, Langaker KE, Bonifazi F, Harris TAG. Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: A comparison of 1 year. Respir Med 1996;90:609-617
15. Bootsma GP, Dekhuijzen R, Festen J, Mulder PGH, Swinkels LMJW, van Herwaarden CLA. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 1996;153:924-930
16. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radfin M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400 μg/day in mild and moderate asthma. Arch Dis Child 1993;69:206-211
17. Pauwels R, Demedts MG, Yernault JC, Gusens P, Roosens WA. Comparison of long term safety and efficacy of fluticasone propionate and beclomethasone dipropionate in combination with salmeterol in patients with moderate to severe asthma. Am J Respir Crit Care Med 1995;151 (suppl):A276
18. Backman R, Pickering CA, Baumgarten C, Huskisson SC. Fluticasone propionate diskus 250 μg bd compared with budesonide turbohaler 600 μg bd in adult asthmatics. J Allergy Clin Immunol 1996;97:A267
19. Leblanc P, Mink S, Keistinen T, Saarelainen P, Ringdal N, Payne SI. Comparison of fluticasone propionate 200 μg/ day with beclomethasone dipropionate 400 μg/day in adult asthma. Allergy 1994;49:380-385
20. Gross G, Wolfe J, Noonan M, et al. Fluticasone propionate 500 μg/day improves asthma more than triamcinolone acetonide 800 μg/day. Am J Respir Crit Care Med 1996; 153(suppl):A340
21. Dahlberg E, Thalen A, Brattsand R, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α, 17αacetal-substituted glucocorticoids. Mol Pharmacol 1984;25:70-78
22. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602
23. Miller-Larsson A, Mattsson H, Ohlsson D, et al. Prolonged release from the airway tissue of glucocorticoids budesonide and fluticasone propionate and hydrocortisone. Am J Respir Crit Care Med 1994;149(suppl):A466
24. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997;43:155-161
25. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from turbuhaler is twice that from a pressurised metered dose inhaler. Eur Respir J 1994;7:1839-1844
26. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davis P, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Resp Dis 1982;63 (suppl 122):86-95
27. Chaplin MD, Rooks W, Swenson EW, Cooper WC, Neranberge C, Schu NI. Flunisolide metabolism and dynamics of a metabolite. J Allergy Clin Immunol 1980;27:402-413
28. Derendorf H, Hochhaus G, Rohatagi S. Pharmacokinetics of triamcinolone acetonide after intravenous, oral and inhaled administration. J Clin Pharmacol 1995;35:302-305
29. Falcoz Z, Kergy SM, Smith J, Olsson P, Ventresca GP. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J 1996;9(suppl 23):162S
30. Lonnebo A, Grahnen A, Jansson B, Brunden RM, Ling-Andersson A. An assessment of the systemic effects of single repeated doses of inhaled fluticasone propionate, in inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996;49:459-463
31. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996;42:697-705
32. Andersson P, Ryrfeldt A. Biotransformation of the topical glucocorticoids, budesonide and beclomethasone, 17,21-diaproprionate in human liver and lung homogenate. J Pharm Pharmacol 1984;36:763-765
33. Wurthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990;11:381-394
34. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84(suppl A):25-29
35. Heald D, Argenti D, Jensin B, Ferccaro S. Disposition of 14c triamcinolone acetonide administered as single oral dose of 100 Ci to healthy volunteers. In: Proceedings of a joint meeting of the American Academy of Allergy, Asthma, Immunology and the American Thoracic Society, in cooperation with the American College of Chest Physicians. Asthma 1995 Conference: Theory to Treatment; July 15-17, 1995; Chicago, IL, p. 14
36. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce systemic effects of high dose inhaled conicosteroids. Thorax 1990;45:736-739
37. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled conicosteroids from a metered dose inhaler and dry-powder inhaler. Thorax 1991;46:891-894
38. Toogood JH, Baskerville J, Jennings B, Neville M, Lefcoe NM, Johannsson SA. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984;129:723-729
39. Trescoli-Serrano C, Ward MJ, Rajput R, Garcia-Zorcaco M. Does swallowing charcoal affect gastrointestinal absorption of inhaled beclamethasone. Eur Respir J 1995;8:S304
40. Brown PH, Matusiewicz S, Seharing C, Tibi L, Greening AP, Crompton GK. Systemic effects of high dose inhaled steroids: comparison of beclomethasone and budesonide in healthy subjects. Thorax 1993;48:967-973
41. Lipworth BJ, Clark DJ. Effects of airway calibre on the lung delivery of nebulised salbutamol. Thorax 1997;52:1036-1039
42. Agertoft L, Pedersen S. A randomised double-blind dose reduction study to compare the minimal effective dose of budesonide turbuhaler and fluticasone propionate diskhaler. J Allergy Clin Imunol 1997;99:773-780
43. Toogood JH, Lefcoe NM, Haines DSM, et al. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 1977;59:298-308
44. Kraan J, Coeter GH, Van der Mark TW, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988;137:44-48
45. Polosa R, Holgate ST. Adenosine bronchoprovocation: A promising marker of allergic inflammation in asthma. Thorax 1997;52:919-923
46. O'Byrne PM, Hargreave FE. Non-invasive monitoring of airway inflammation. Am J Respir Crit Care Med 1994;150: S100-S102
47. Kaharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 1996;9:196-201
48. Agertoft L, Pedersen S. Relationship between short term lower leg growth and long term statural growth in asthmatic children treated with budesonide. Eur Respir J 1996;9(suppl):294S
49. Lipworth BJ, Seckl JL. Measures for detecting systemic bioactivity with inhaled and intranasal conicosteroids. Thorax 1997;52:476-482
50. Bikle DD. Biochemical markers in the assessment of bone disease. Am J Med 1997;103:427-436
51. Welch MJ, Levey S, Smith JA, Feiss G, Farrar JR. Dose-ranging study of the clinical effacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest 1997;112:597-606
52. Nathan RA, Nolop KB, Cuss FM, Lorber RR. A comparison of double-strength beclomethasone dipropionate (84 μg) MDI with beclomethasone dipropionate (42 μg) MDI in the treatment of asthma. Chest 1997;112:34-39
53. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995;95:29-33
54. Ayres JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995;8: 579-586
55. McCubbin MM, Milavetz G, Grandgeorge S, et al. A bioassay for topical and systemic effect of 3 inhaled corticosteroids. Clin Pharmacol Ther 1995;57:445-460
56. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisolone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995;152:1467-1473
57. Cheninsky P, Van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994;94:676-683
58. Wolfe J, Hampel F, Goldstein M, et al. Efficacy and safety of fluticasone propionate (FP) metered dose inhaler in patients with moderate asthma. J Allergy Clin Immunol 1994;93:186
59. Busse WW, Chervinsky P, Loncheni J, Lumry W, Petty T, Rennard S, Townley R. Budesonide delivered by turbuhaler is effective in a dose dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457-463
60. Dahl R, Lundback B, Malo JM, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993;104:1352-1358
61. Hummel S, Lehtonen L, Study Group. Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma. Lancet 1998; 340:1483-1487
62. Boe J, Rosenhall L, Alton M, et al. Comparison of dose-response effects of inhaled beclomethasone diproprionate and budesonide in the management of asthma. Allergy 1989;44:349-355
63. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johannsson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989;84:668-700
64. Johannsson SA, Dahl R. A double-blind dose-response study of budesonide by inhalation in patients with bronchial asthma. Allergy 1998;43:173-178
65. Tukiainen P, Lahdensuo A. Effect of inhaled budesonide on severe steroid-dependent asthma. Eur J Respir Dis 1987; 70:239-244
66. Laursen LC, Taudorf E, Weeke B. High-dose inhaled budesonide in treatment of severe steroid-dependent asthma. Eur J Respir Dis 1986;68:19-28
67. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johannsson SA. Influence of the dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Clin Immunol 1982;70: 288-298
68. British Thoracic and Tuberculosis Association. A controlled trial of inhaled corticosteroids in patients receiving prednisone tablets for asthma. Br J Dis Chest 1976;70:95-103
69. Brompton Hospital/Medical Research Council Collaborative Trial. Double blind trial comparing two dose schedules of beclomethasone dipropionate aerosol and the treatment of chronic bronchial asthma. Lancet 1974;23: 303-307
70. Brompton Hospital/Medical Research Council Collaborative Trial. Double blind trial comparing two dosage schedules of beclomethasone dipropionate aerosol with placebo in chronic bronchial asthma. Br J Dis Chest 1979;73:121-122
71. Gaddie J, Reid IW, Skinner C, Petrie GR, Sinclair DJ, Palmer KN. Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma. Lancet 1973;2: 280-281
72. Olsson B. Aerosol particle generation from dry-powder inhalers - can they equal pressurized metered dose inhalers? J Aerosol Med 1995;8:S13-S19
73. McIntyre DH, Mitchell CA, Bowler SD, Armstrong JG, Wooler JA, Cowlie DM. Measuring the systemic effects of inhaled beclomethasone: Timed morning urine collections compared with 24 hour specimens. Thorax 1995; 51:281-284
74. Lipworth BJ, Wilson AM. 24 hour adrenocortical profiles in asthmatics receiving inhaled and intranasal corticosteroids. J Allergy Clin Immunol 1998;101(suppl part2):S8
75. Crowley S, Hindmarsh PC, Hownia P, Honor JW, Brook CGD. The use of low doses of ACTH in the investigation of adrenal function in man. J Endocrinol 1991;130: 475-479
76. Crowley S, Hindmarsh PC, Honor JW, Brook CGD. Reproducibilily of the cortisol response to simulation with a low dose of ACTH (1-24): The effect of basal cortisol levels in comparison of low dose with high dose secretory dynamics. J Endocrinol 1993;136:107-172
77. Rasmuson S, Olsson T, Hagg E. A low dose ACTH test to access the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol 1991;44:151-156
78. Broide J, Soferman R, Kivity S, et al. Low dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab 1995;80:1243-1246
79. Brown PH, Blundell G, Greening AP, Crompton GK. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high doses of inhaled corticosteroid. Respir Med 1991;85:511-516
80. Schlanghecke R, Kornely E, Santen R, Ridderskam P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin releasing hormone. New Eng J Med 1992;326:226-230
81. Clark DJ, Lipworth BJ. Evaluation of corticotropin releasing factor stimulation and basal markers of HPA-axis suppression in asthmatic patients. Chest 1997;112:1248-1252
82. Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994;38:521-525
83. Padfield PL, Teelucksingh S. Inhaled corticosteroids: The endocrinologists view. Eur Respir Rev 1993;3:494-500
84. Donnelly R, Williams KM, Baker B, Badcock CA, Day RO, Seal PJ. Effects of budesonide and fluticasone on 24 hour plasma cortisol: A dose response study. Am J Respir Crit Care Med 1997;156:1746-1751
85. Grahnen A, Jansson B, Brunden RM, et al. A dose response study comparing suppression of plasma cortisol induced by fluticasone propionate from diskhaler and budesonide from terbuhaler. Eur J Clin Pharmacol 1997;52:261-267
86. Lipworth BJ, Wilson AM. Dose response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. J Allergy Clin Immunol 1998;101(suppl part 2):S6
87. Wilson AM, Lipworth BJ. A chronic dosing comparison of the systemic bioactivity with oral prednisolone and nebulised budesonide in adult asthmatic patients. Br J Clin Pharmacol 1998;45:185P
88. Wilson AM, McFarlane LC, Lipworth BJ. Dose response effect for adrenal suppression with repeated twice daily inhaled fluticasone priopionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med 1997;156:1274-1277
89. Wilson AM, Lipworth BJ. Systemic dose-response relationships with oral and inhaled corticosteroid in asthmatics. Thorax 1997;52(suppl 6):A57
90. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996;9:1427-1432
91. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-266
92. Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by a large volume spacer in asthmatic children. Thorax 1996;51:941-943
93. Jennings BH, Anderson KE, Johannsson SA. Assessment of systemic effects of inhaled glucocorticoids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1989;40:77-82
94. Johansson SA, Andersson K, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis 1982;63(suppl 122): 74-82
95. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997;52:55-58
96. Wilson AM, McFarlane LC, Lipworth BJ. Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healty volunteers. J Clin Endocrinol Metab 1998;83:922-925
97. Agertoft L, Pedersen S. Short term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: A dose response study. Eur Respir J 1997;10:1507-1512
98. Pedersen S, Fugslang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: A comparison of budesonide and beclomethasone. Eur Respir J 1988;1:433-435
99. Bisgaard H, Damkjaer Nielsen M, Andersen B, et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988;81:1088-1095
100. Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamo-pituitary-adrenal axis suppression in asthmatics taking inhaled high dose corticosteroids. Respir Med 1991;85:501-510
101. Sorkness CA, Howland WC, Stricker WE, et al. Comparison of inhaled fluticasone propionate and triamcinolone acetonide: Effects on the HPA-axis as assessed by 6 hour cosyntropin infusion testing. Eur Respir J 1996;9(suppl 23):163S
102. Kellerman DJ, Stricker W, Howland W, et al. Effects of inhaled fluticasone propionate on the HPA-axis of patients with asthma. Eur Respir J 1996;9(suppl 23):162S
103. Altman LC, Findlay SR, Lopez M, et al. Adrenal function in adult asthmatics during long term daily treatment with 800, 1200 and 1600 μg triamcinolone acetonide. Chest 1992;100:1250-1251
104. Ninan TK, Reid IW, Carter PE, Smail P, Russell G. Effective high doses of inhaled corticosteroids on adrenal function in children with severe persistant asthma. Thorax 1993; 48:599-602
105. Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of inhaled fluticasone propionate and budesonide given via large volume spacer to asthmatic school children. Thorax 1997;52:686-689
106. Derom E, Van Schoor A, Vincken W, et al. A comparison of the systemic activity of two doses of inhaled fluticasone propionate and budesonide in asthmatic patients. Am J Respir Crit Care Med 1997;155(suppl):A355
107. Harrison LI, Purrington A, Leitch C, Machaek J, Van Den Burgt J, Vogel J. Manificial effects of reduced particle size of CFC-free extra fine aerosol steroid on lung deposition, absorption, efficacy and safety. Am J Respir Crit Care Med 1997;155(suppl):A666
108. Sherman B, Weinbeger M, Chen-Walden H, Wendt H. Further studies of the effects of inhaled glucocorticoids on pituitary-adrenal function in healthy adults. J Allergy Clin Immunol 1982;69:208-212
109. Wilson AM, Clark DJ, Devlin M, McFarlane LC, Lipworth BJ. Adrenocortical activity with repeated administration of once daily inhaled fluticasone propionate and budesonide in asthamtic adults. Eur J Clin Pharmacol 1998; 53:317-320
110. Wolthers OD, Pedersen S. Measures of systemic activity of inhaled corticosteroids in children: a comparison of urine cortisol excretion and knemometry. Respir Med 1995;89: 347-349
111. Wolthers OD, Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child 1993;68: 673-676
112. Wolthers O, Pedersen S. Controlled study of linear growth in asthmatic children during treatment with inhaled glucocorticosteroids. Pediatrics 1992;89:839-842
113. Wolthers O, Pedersen S. Growth of asthmatic children during treatment with budesonide: A double-blind trial. BMJ 1991;303:163-165
114. Allen OB, Bronsky EA, LaForce CF, et al. Growth in children treated with fluticosone proponate. J Pediatr 1998;132: 472-477
115. McCowan C, Neville RG, Thomas GE, et al. Effect of asthma and its treatment in growth: Four year follow-up of cohort of children from general practices in Tayside, Scotland. Br Med J 1998;316:668-672
116. Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: Effect of glucocorticoid therapy. J Allergy Clin Immunol 1997;99:466-474
117. Agertoft L, Pedersen S. Effects of long term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88:373-381
118. Littlewood JM, Johnson AW, Edwards PA, Littlewood AE. Growth retardation in asthmatic children treated with inhaled beclomethasone dipropionate. Lancet 1998;1:115-116
119. Nassif E, Weinburger M, Sherman B, Brown K. Extrapulmonary effects of maintenance corticosteroid therapy with alternate day prednisolone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol 1987;80:518-529
120. Simons FER. A comparison of beclomethasone, salmeterol and placebo in children with asthma. N Engl J Med 1997;337:1659-1665
121. Verberne AAPH, Frost C, DipStat MA, et al. One-year treatment with salmeterol compared to beclomethasone in children with asthma. Am J Crit Care Med 1997;156:688-695
122. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic mild to moderately severe asthma in children. Pediatrics 1993;92:64-77
123. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967-976
124. Merkus PJFM, van Essen-Zandvliet EM, Durverman EG, van Houwelingen HC, Kerrebijn KF, Quanjer PH. Long term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics 1993;6:1121-1126
125. Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986;61:1049-1055
126. Crowley S, Hindmarsh PC, Mathews DR, Brook CGD. Growth and the growth hormone axis in prepubertal children with asthma. J Pediatr 1995;1:297-303
127. Wasnich R. Bone mass measurement: Prediction of risk. Am J Med 1993;95(suppl 5A):6S-10S
128. Wolthers OD, Hansen M, Juul A, Nielson HA, Pedersen S. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor access and collagen turnover in children treated with inhaled glucocorticosteroids. Ped Res 1997;41:44-50
129. Wolthers OD, Juul A, Hansen M, Muller J, Pedersen S. The insulin-like growth factor axis and collagen turnover in asthmatic children treated with inhaled budesonide. Acta Paediatr 1995;84:393-397
130. Hodsman AB, Toogood JH, Jennings B, Fraher LJ, Baskerville JC. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab 1991;72:530-540
131. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 1991;338:60-61
132. Toogood JH, Jennings B, Hodsman AB, Baskerville J, Fraher LJ. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol 1991; 88:572-580
133. Lipworth BJ, Clark DJ. High dose inhaled steroids in asthmataic children. Lancet 1996;348:820
134. Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrel H, Tattersfield AE. Cross section investigation of the affects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax 1997;52:853-860
135. Hanania NA, Chapman KR, Sturtridge WC, Szalii JP, Kesten S. Dose related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96:571-579
136. Konig P, Hillman G, Gervantes C. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr 1993;122:219-226
137. Toogood JH, Baskerville J, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-166
138. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994;105:1722-1727
139. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long term treatment with inhaled budesonide. Am J Respir Crit Care Med 1998;157:178-183
140. Luengo M, del Rio L, Pons F, Picado C. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: A case control study. Eur Respir J 1997;10:2110-2113
141. American College of Rheumatology Task Force on Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rhem 1996;39:1791-2081
142. Urban RC, Cotlier E. Corticosteroid induced cataracts. Surv Ophthalmol 1986;31:102-110
143. Kewley GD. Possible association between beclomethasone dipropionate aerosol and cateracts. Aust Paed J 1980;60: 117-118
144. Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen P. Steroid aerosols and cataract formation. BMJ 1989;299:432-433
145. Fraunfelder FT, Meyer SM. Posterior subcapsular cataracts associated with nasal or inhaled corticosteroids. Am J Opthalmol 1990;109:489-490
146. Rooklin AR, Lampert SI, Jaeger EA, McGeady J, Mansmann HCJ. Posterior subcapsular cateracts in steroid requiring asthmatic children. J Allergy Clin Immunol 1979;63:383-386
147. Shun-Shin GA, Brown NP, Bron AJ, Sparrow JM. Dynamic nature of posterior subcapsular cataract. Br J Ophthalmol 1989;73:522-527
148. Toogood JH, Markov AE, Baskerville J, Dyson C. Association of ocular cataracts with inhaled and oral steroid therapy during long term treatment of asthma. J Allergy Clin Immunol 1993;91:571-579
149. Simons FER, Persaud MP, Gillespie CA, Chang M, Shuckett EP. Absence of posterior subcapsula cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993; 342:776-778
150. Abuekteish F, Kirkpatrick JNP, Russell G. Posterior subcapsula cataract and inhaled corticosteroid therapy. Thorax 1995;50:674-676
151. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risks of cataracts. New Engl J Med 1997;3:3378-4014
152. Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995;102:177-179
153. Dreyer EB. Inhaled steroid use in glaucoma. N Engl J Med 1993;329:1822
154. Garb E, Le Lorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open angle glaucoma. JAMA 1997;277:722-727
155. Capewell S, Renalds S, Shuttleworth D, Edward C, Finlay AY, Pupura and Denand. Andermal thinning associated with high dose inhaled corticosteroids. BMJ 1990;300:1548-1551
156. Mak VHF, Melchor R, Spiro SG. Easy bruising is a side effect of inhaled corticosteroids. Eur Respir J 1992;5:1068-1074
157. Roy A, Le Blanc C, Paquete L, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency in association with adrenal function. Eur Respir J 1996;9:226-231
158. Blaiss MS, Herrod HG, Crawford LV, Liebermann PL. Beclomethasone dipropionate aerosol: Haemotologic and immunologic effects. Ann Allergy 1982;48:210-214